Entering text into the input field will update the search result below

Albireo Pharma nabs Rare Pediatric Disease tag for A4250 for rare liver disorder; shares up 7% premarket

Jun. 12, 2018 9:06 AM ETAlbireo Pharma, Inc. (ALBO) StockBy: Douglas W. House, SA News Editor1 Comment
  • Thinly traded micro cap Albireo Pharma (NASDAQ:ALBO) is up 7% premarket on light volume on the heels of its announcement that the FDA has granted Rare Pediatric Disease Designation for lead drug A4250 for the treatment of a rare life-threatening liver disease called progressive familial intrahepatic cholestasis (PFIC), an Orphan Drug indication in the U.S. and Europe.
  • If A4250 is approved, the company will receive a Rare Pediatric Disease Priority Review Voucher that it can use for accelerated review for a future marketing application or it can sell it to a third party.
  • A4250, an ileal bile acid transporter inhibitor, is currently in Phase 3 development for PFIC.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ALBO--
Albireo Pharma, Inc.